🇺🇸 FDA
Pipeline program

DEXAMETHASONE , MK-2870, -, -, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

MK-2870-007

Phase 3 small_molecule active

Quick answer

DEXAMETHASONE , MK-2870, -, -, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, KEYTRUDA 25 mg/mL concentrate for solution for infusion, - for Metastatic non-small cell lung cancer (NSCLC) is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Metastatic non-small cell lung cancer (NSCLC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials